Scandion Oncology A/S (TO 1)
Scandion Oncology A/S is a biotechnology company addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of drug resistant cancers which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now initiating clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer.
Läs mer på företagets hemsidaDetaljinfo & filer
- Teckningstid:
- 10/9 - 01/10 2020
- Typ:
- Optionsinlösen